secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merus N.V. (—)
CIK:        0001651311
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001193125-25-316841
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merus completes $6.9B acquisition by Genmab at $97.00 per share; 94.2% tendered
-------------------------------------------------------------------------------

- Acquisition closed Dec 12, 2025; total consideration ~$6.9B; shareholders received $97.00 per share in cash.
- 94.2% of outstanding shares validly tendered and accepted; subsequent offering period runs through Dec 29, 2025.
- Board changes: Sven Lundberg, Mark Iwicki, Len Kanavy, Paolo Pucci, Victor Sandor, Jason Haddock departed; Jan van de Winkel appointed CEO.
- Executives Lundberg and Silverman cease as officers; gross-up agreements with aggregate cap of $9.3M for certain executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651311/000119312525316841/0001193125-25-316841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651311/000119312525316841/d29730d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-316841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer